News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
674,501 Results
Type
Article (38553)
Company Profile (191)
Press Release (635757)
Section
Business (202843)
Career Advice (1957)
Deals (35334)
Drug Delivery (74)
Drug Development (80454)
Employer Resources (167)
FDA (15930)
Job Trends (14752)
News (342692)
Policy (32378)
Tag
Academia (2524)
Africa (708)
Allergies (37)
Alliances (48859)
Alzheimer's disease (1093)
Antibody-drug conjugate (ADC) (43)
Approvals (15873)
Arizona (159)
Artificial intelligence (48)
Asia (36567)
Australia (5944)
Bankruptcy (350)
Best Places to Work (11172)
Biosimilars (55)
C2C Services and Suppliers (78801)
California (820)
Canada (641)
Cancer (176)
Career advice (1635)
CAR-T (32)
Cell therapy (65)
China (48)
Clinical research (62581)
Collaboration (56)
Colorado (33)
Compensation (30)
COVID-19 (2452)
Cystic fibrosis (69)
Diabetes (32)
Diagnostics (5888)
Diversity, equity & inclusion (44)
Drug pricing (47)
Earnings (82757)
Employer resources (141)
Europe (78084)
Events (106897)
FDA (15974)
Florida (106)
Funding (37)
Gene therapy (52)
GLP-1 (465)
Government (4272)
Healthcare (18525)
Hotbed/Location (481031)
Idaho (55)
Illinois (194)
Indiana (105)
Infectious disease (2465)
Inflammatory bowel disease (83)
Interviews (305)
IPO (16114)
Job creations (3616)
Job search strategy (1410)
Kansas (90)
Layoffs (372)
Legal (7814)
Liver cancer (51)
Lung cancer (37)
Maine (47)
Management (53)
Manufacturing (45)
Maryland (251)
Massachusetts (450)
Medical device (12944)
Medtech (12947)
Mergers & acquisitions (18921)
Metabolic disorders (154)
Neuroscience (1170)
New Jersey (62)
New York (83)
NextGen Class of 2024 (6445)
Non-profit (4441)
North Carolina (158)
Obesity (101)
Opinion (160)
Parkinson's disease (29)
Patents (33)
Peanut (33)
Pennsylvania (55)
People (55518)
Phase I (19400)
Phase II (27568)
Phase III (20611)
Policy (33)
Postmarket research (2544)
Preclinical (8270)
Rare diseases (89)
Real estate (5877)
Recruiting (63)
Regulatory (21011)
Reports (32)
Research institute (2297)
Resumes & cover letters (343)
South America (1085)
Startups (3547)
Texas (87)
United States (3002)
Vaccines (408)
Washington State (113)
Weight loss (96)
Date
Today (45)
Last 7 days (496)
Last 30 days (1908)
Last 365 days (38255)
2024 (21594)
2023 (40074)
2022 (51174)
2021 (55714)
2020 (54087)
2019 (46544)
2018 (35021)
2017 (32112)
2016 (31480)
2015 (37554)
2014 (31318)
2013 (26346)
2012 (28570)
2011 (29263)
2010 (27328)
674,501 Results for "chemocentryx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI).
October 20, 2022
·
14 min read
Business
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
Immuneering Corporation today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors.
March 12, 2024
·
2 min read
Deals
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., today announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion.
August 4, 2022
·
16 min read
Business
ChemoCentryx Announces Changes to its Board of Directors
ChemoCentryx, Inc., announced changes to the composition of its Board of Directors.
May 31, 2022
·
4 min read
Business
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET.
August 9, 2022
·
7 min read
Business
ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022.
July 5, 2022
·
4 min read
Biotech Bay
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned presentations covering TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, at the American Society of Nephrology (ASN) Kidney Week 2022 and American College of Rheumatology (ACR) Convergence 2022 annual meetings taking place in November.
October 17, 2022
·
10 min read
Business
ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022.
August 2, 2022
·
2 min read
Biotech Bay
ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS® (avacopan).
May 31, 2022
·
8 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
3 min read
·
Voyager Therapeutics, Inc.
1 of 67,451
Next